Skip to main content
Premium Trial:

Request an Annual Quote

Co-Diagnostics Receives PCR Technology from DNA Logix

NEW YORK (GenomeWeb News) – Co-Diagnostics said recently that certain real-time PCR technology has been transferred to the company from DNA Logix.

DNA Logix transferred four patents and applications pursuant to a purchase agreement between the two firms. Under the terms of the agreement, Co-Diagnostics, based in Salt Lake City, exercised its option to purchase the technology related to real-time PCR diagnostics testing.

The patents and applications that were transferred are titled, "Methods of Preventing Non-Specific Reactions of Nucleotide Sequences;" "Rapid Oligo Probes;" "Detection Primers for Nucleic Acid Extensions or Amplification Reactions;" and "Primers for Nucleic Acid Extension or Amplification Reactions."

In a statement, Co-Diagnostics President Dwight Egan said that "the patents transferred contain cutting-edge technology in the molecular diagnostic testing industry and represent a breakthrough that will enable testing to be performed much less expensively than is standard in the industry at the present time."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.